155 results
8-K
EX-99.1
RSPI
RespireRx Pharmaceuticals Inc.
22 Jan 24
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
8:45am
further believe that its repurposing strategy would only require, in the United States, approval by the FDA of a 505(b)(2) new drug application (“NDA … , assumptions, financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about research
8-K
EX-99.1
RSPI
RespireRx Pharmaceuticals Inc.
11 Dec 23
Entry into a Material Definitive Agreement
8:45am
, Treasurer and Secretary in driving these efforts.
Mr. Clodfelter has extensive experience providing business development, strategy, and valuation … , biotechnology and medical device companies. He previously held positions at Eli Lilly and Co. in Corporate Strategy and Business Development. He
8-K
EX-99.1
RSPI
RespireRx Pharmaceuticals Inc.
12 Oct 23
RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services
9:00am
nausea and vomiting, RespireRx and ResolutionRx further believe that its repurposing strategy would only require, in the United States, approval … , business strategy and other plans and objectives for future operations, and assumptions and predictions about research and development efforts
8-K
EX-10.4
xcpzk
9 Aug 23
RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company
8:52am
8-K
EX-99.1
hu4ax3buw 5fl
9 Aug 23
RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company
8:52am
8-K
EX-99.1
d3r5 gjmd5101j06
24 May 23
Entry into a Material Definitive Agreement
8:45am
8-K
EX-99.1
ks3cr9
17 Nov 22
Regulation FD Disclosure
9:00am
8-K
EX-99.1
fzxwekjhtdz7t3ikducx
10 Nov 22
RespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4
9:00am
8-K
EX-99.1
6cz8dz0ge2
7 Nov 22
RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa Is an Invited Speaker at the 5th Meridian Drug Discovery Summit
9:00am
8-K
EX-99.1
7k0sxa
23 Mar 22
Regulation FD Disclosure
8:30am
253G2
dtrmhkr3g y4bcr
8 Mar 22
Offering circular supplement
4:05pm
8-K
EX-99.1
0w2xmusz0fbiz0ptasj0
7 Mar 22
Regulation FD Disclosure
8:15am